 |
|
|
|
|
|
|
| Article 1 to 10 out of 33 concerning Bristol-Myers Squibb Co.
|
-
Bristol-Myers Squibb Announces Closing of Its Barceloneta, Puerto Rico Plant
(22 Jan 2008)
Bristol-Myers Squibb Company announced it will cease operations at its Barceloneta manufacturing plant by the end of 2008. The closure of the Barceloneta site is a result of the decrease in market demand for a number of the mature products produced ...
-
Bristol-Myers Squibb to pay more than $515 million to resolve allegations of illegal drug marketing & pricing
(02 Oct 2007)
Bristol-Myers Squibb Company (BMS) and its wholly owned subsidiary, Apothecon, Inc., have agreed to pay over $515 mln to resolve a broad array of civil allegations involving their drug marketing and pricing practices, US Attorney Michael J. Sullivan ...
-
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
(29 Aug 2007)
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
Pfizer Inc and Bristol-Myers Squibb Company announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT-1 discovery program includes advanced ...
-
Bristol-Myers Squibb Announces Discontinuation Of Development Of Investigational Oral Treatment For Type 2 Diabetes
(22 May 2006)
Bristol-Myers Squibb Company announced that it has discontinued the development of muraglitazar, a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) agonist in development for type 2 diabetes and will focus its efforts on other ...
-
Bristol-Myers Squibb Company Names David I. Johnson President Of ConvaTec
(19 Apr 2006)
Bristol-Myers Squibb Company announced that David I. Johnson has been named President, ConvaTec. As president, Mr. Johnson will have responsibility for all aspects of the worldwide ConvaTec business. He will be based at ConvaTec global headquarters ...
-
Sanofi-aventis And Bristol-Myers Squibb Announce Agreement To Settle U.S. Plavix Litigation With Apotex
(23 Mar 2006)
Sanofi-aventis and Bristol-Myers Squibb Company announced that they have reached an agreement subject to certain conditions with Apotex Inc. and Apotex Corp. to settle the patent infringement lawsuit pending between the parties in the U.S. District ...
-
Bristol-Myers Squibb Company Closes Previously Announced Sale Of U.S. And Canadian Consumer Medicines Business
(02 Sep 2005)
Bristol-Myers Squibb Company reported that it has completed the previously announced sale of its U.S. and Canadian Consumer Medicines business to Novartis AG.As previously disclosed, the transaction includes rights to Bristol-Myers Squibb's U.S. ...
-
Sigma-Aldrich Joins RNAi Consortium
(17 Mar 2005)
Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute ...
-
Bristol-Myers Squibb Completes Sale Of Clairol To Procter & Gamble
(20 Nov 2001)
NEW YORK, NEW YORK -- Bristol-Myers Squibb Company (NYSE:BMY) announced today that the sale of its Clairol beauty care subsidiary to The Procter & Gamble Company for $4.95 billion has been finalized. The divestiture, which was announced on May 21 ...
-
Bristol-Myers Squibb And Otsuka Pharmaceutical Co., Ltd., Submit New Drug Application For Aripiprazole
(08 Nov 2001)
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Company, Ltd. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for aripiprazole, an investigational novel drug ...
|
|
|
|
|
Top